증상 발현 후 4.5-24시간 이내 급성 허혈성 뇌졸중 환자에서의 단회 투여 비면역원성 스타필로키나제 (FRIDA-CT)
증상 발현 후 4.5~24시간 이내 급성 허혈성 뇌졸중 환자에서 재조합 비면역원성 포도상구균효소의 유효성 및 안전성에 대한 다기관, 이중맹검, 무작위, 위약대조 연구 (FRIDA-CT)
Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus injection of the recombinant non-immunogenic staphylokinase (Fortelyzin®, LLC "SuperGene", Russia) or placebo.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The current guidelines recommended intravenous thrombolysis as the first-line treatment for acute large vessel occlusion of anterior circulation stroke within 4.5 hours of stroke onset. However, a majority of patients arrive in the hospital outside the 4.5-hour time window, who could not receive intravenous thrombolysis.
In 2020, the non-immunogenic staphylokinase was registered in Russia for the acute ischemic stroke treatment within 4,5 h after the onset of symptoms. In the FRIDA randomized clinical trial the non-immunogenic staphylokinase was non-inferior to alteplase for patients with acute ischaemic stroke. Mortality, symptomatic intracranial haemorrhage, and serious adverse events did not differ significantly between groups. Non-immunogenic staphylokinase is easy to administer with a rapid single bolus of 10 mg regardless patients' bodyweight, simplifying clinical use. In 2024, the non-immunogenic staphylokinase has been included in the updated Russian clinical guidelines for the acute ischemic stroke treatment.
A rapid (10 s) single bolus of the non-immunogenic staphylokinase in patients with acute ischemic stroke may provide significant advantages over a one-hour alteplase administration in the more rapid reperfusion in the first 24 hours after thrombolysis and a greater number of good functional outcomes. It can be assumed that the non-immunogenic staphylokinase usage in patients with acute ischemic stroke outside the 4.5-hour therapeutic window will lead to the restoration of collateral blood flow in the penumbra in comparison with standard medical management.
Therefore, FRIDA-CT trial is aimed to investigate the efficacy and safety of the non-immunogenic staphylokinase within the time window of 4.5-24 hours, wake-up stroke or no witness stroke in patients who had an acute ischaemic stroke with salvageable tissue due to large vessel occlusion.
In the multicenter, double-blind, randomized, placebo-controlled phase III clinical trial patients who had an acute ischaemic stroke due to anterior circulation large vessel occlusion (internal carotid artery, middle cerebral artery M1 and M2 segments) within 4.5-24 hours from last known well (including wake-up stroke and no witness stroke) and with salvageable tissue (ischaemic core volume <70 mL, mismatch ratio ≥1.8 and mismatch volume ≥15 mL) based on CT perfusion or MRI perfusion-weighted imaging (PWI) will be included and randomised to the non-immunogenic staphylokinase, 10 mg (single bolus) regardless patient's bodyweight or placebo group. Patients who are intended for direct thrombectomy will be excluded from the trial. Follow-up period will be 90 days.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Nikolay A. Shamalov, MD, prof
- 전화번호: +7 (499) 936-99-37
- 이메일: shamalovn@gmail.com
연구 연락처 백업
- 이름: Natalya A. Marskaya
- 전화번호: +7 (499) 936-99-37
- 이메일: marskayana@gmail.com
연구 장소
-
-
-
Chelyabinsk, 러시아 제국
- 모병
- Chelyabinsk Regional Clinical Hospital No. 3
-
연락하다:
- Dmitry V. Popov, PhD
- 이메일: Dmitry_popov2001@mail.ru
-
수석 연구원:
- Dmitry V. Popov, PhD
-
Irkutsk, 러시아 제국, 664079
- 모병
- Irkutsk Regional Clinical Hospital
-
연락하다:
- Ivan V. Korobeynikov, PhD
- 이메일: Irk.ivan@gmail.com
-
수석 연구원:
- Ivan V. Korobeynikov, PhD
-
Kazan', 러시아 제국, 420101
- 모병
- Interregional Clinical and Diagnostic Center
-
연락하다:
- Dina R. Khasanova, MD, Prof
- 이메일: dhasanova@mail.ru
-
수석 연구원:
- Dina R. Khasanova, MD, Prof
-
Krasnodar, 러시아 제국, 350086
- 모병
- S.V. Ochapovsky Research Institute - Regional Clinical Hospital No. 1
-
연락하다:
- Ludmila V. Timchenko, MD, prof
- 이메일: tlv2908@yandex.ru
-
수석 연구원:
- Ludmila V. Timchenko, MD, prof
-
Krasnogorsk, 러시아 제국, 143408
- 모병
- Krasnogorsk Clinical Hospital
-
연락하다:
- Svetlana V. Alexandrova
- 전화번호: +7 (498) 602-03-73
- 이메일: clairalex@mail.ru
-
수석 연구원:
- Svetlana V. Alexandrova
-
Moscow, 러시아 제국, 108814
- 모병
- Moscow Multidisciplinary Clinical Center "Kommunarka"
-
연락하다:
- Denis N. Protsenko, PhD
- 전화번호: +7 (495) 744-07-03
- 이메일: ProtsenkoDN@zdrav.mos.ru
-
수석 연구원:
- Denis N. Protsenko, PhD
-
Moscow, 러시아 제국, 117997
- 모병
- N.I. Pirogov Russian National Research Medical University
-
연락하다:
- Larisa L. Korsunskaya, MD, Prof
- 이메일: neurocrimea@mail.ru
-
수석 연구원:
- Larisa L. Korsunskaya, MD, Prof
-
Nizhny Novgorod, 러시아 제국, 603126
- 아직 모집하지 않음
- N.A. Semashko Nizhny Novgorod Regional Clinical Hospital
-
연락하다:
- Valentina N. Nesterova, PhD
- 전화번호: +7 (831) 438-95-38
- 이메일: nesterova-78@mail.ru
-
수석 연구원:
- Valentina N. Nesterova, PhD
-
Orenburg, 러시아 제국
- 모병
- V.I. Voynov Orenburg Regional Clinical Hospital
-
연락하다:
- Alexandr N. Chirkov, PhD
- 이메일: log82@mail.ru
-
수석 연구원:
- Alexandr N. Chirkov, PhD
-
Saint Petersburg, 러시아 제국, 193079
- 모병
- St. Petersburg Hospital for War Veterans
-
연락하다:
- Maria A. Privalova, PhD
- 전화번호: +7 (812) 670-94-44
- 이메일: privamariya@yandex.ru
-
수석 연구원:
- Maria A. Privalova, PhD
-
Saint Petersburg, 러시아 제국, 194291
- 모병
- Leningradskaya Regional Clinical Hospital
-
연락하다:
- Natalya V. Zhukovskaya, MD, prof
- 이메일: nataly.lokb@mail.ru
-
수석 연구원:
- Natalya V. Zhukovskaya, MD, prof
-
Solnechnogorsk, 러시아 제국, 141508
- 아직 모집하지 않음
- Solnechnogorsk District Hospital
-
수석 연구원:
- Anton G. Koledinsky, MD, PhD
-
연락하다:
- Anton G. Koledinsky, MD, PhD
- 전화번호: +7 (496) 264-14-56
- 이메일: koledant@mail.ru
-
Tver', 러시아 제국, 170036
- 모병
- Tver Regional Clinical Hospital
-
연락하다:
- Ksenia V. Khoroshavina
- 전화번호: +7 (482) 277-54-65
- 이메일: kseniarep@mail.ru
-
수석 연구원:
- Ksenia V. Khoroshavina
-
Ulyanovsk, 러시아 제국
- 모병
- Ulyanovsk Regional Clinical Hospital
-
연락하다:
- Irina V. Greshnova, PhD
- 이메일: tonuus@mail.ru
-
수석 연구원:
- Irina V. Greshnova, PhD
-
Volgograd, 러시아 제국, 400138
- 모병
- City Clinical Hospital of Emergency Medical Care No. 25
-
연락하다:
- Eduard A. Ponomarev, MD, prof
- 이메일: ponomarev67@mail.ru
-
수석 연구원:
- Eduard A. Ponomarev, MD, prof
-
Yekaterinburg, 러시아 제국, 620102
- 모병
- Sverdlovsk Regional Clinical Hospital No. 1
-
연락하다:
- Andrey M. Alasheev, MD, prof
- 이메일: alasheev@live.ru
-
수석 연구원:
- Andrey M. Alasheev, MD, prof
-
-
Ryazan Oblast
-
Ryazan, Ryazan Oblast, 러시아 제국, 390039
- 아직 모집하지 않음
- Ryazan Regional Clinical Hospital
-
연락하다:
- Sergei B. Aksentyev, PhD
- 이메일: aksentievs@mail.ru
-
수석 연구원:
- Sergei B. Aksentyev, PhD
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Men and women aged 18 years and over;
- Acute ischemic stroke symptom onset between 4.5 to 24 hours prior to enrolment, including wake-up stroke and unwitnessed stroke, onset time refers to "last-seen normal time";
- Pre-stroke modified Rankin scale (mRS) score≤1;
- Internal carotid artery, middle cerebral artery M1 or M2 occlusion confirmed by CT/MRI, internal carotid artery, middle cerebral artery M1 or M2 being responsible for signs and symptoms of acute ischemic stroke;
- Neuroimaging: target mismatch profile on CT or MRI perfusion: ischemic core volume <70 mL, mismatch ratio≥1.8 and mismatch volume≥15 mL;
- Alberta Stroke Program Early CT score (ASPECTS) > 6;
- Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (inclusive);
- The patient is not planned or cannot undergo thrombectomy or intravenous thrombolysis in accordance with the current version of the Clinical Guidelines;
- Written informed consent from patients or their legally authorized representatives.
Exclusion Criteria:
- Acute ischemic stroke within 4,5 h after symptom onset;
- Intended to proceed to endovascular treatment;
- Known hypersensitivity to the non-immunogenic staphylokinase;
- Convulsive seizures at the onset of the disease, if there is no certainty that the seizure is a clinical manifestation of acute ischemic stroke;
- Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg), and the inability to reduce systolic blood pressure below 180 mmHg or diastolic blood pressure below 105 mmHg;
- Blood glucose <2.8 or >22.2 mmol/L (after blood glucose level correction to the specified values, inclusion of the patient in the study is possible);
- Neuroimaging (CT, MRI) signs of intracranial hemorrhage, brain tumor, arteriovenous malformation, brain abscess, cerebral aneurysm;
- Subarachnoid hemorrhage;
- Major bleeding currently or within the past 6 months;
- Surgery on the brain or spinal cord in the last 2 months;
- Punctures of non-compressible arteries and veins in the last 7 days;
- Gastrointestinal or genitourinary bleeding in the last 3 weeks. Confirmed exacerbations of gastric ulcer and duodenal ulcer in the last 3 months;
- Platelet count below 100,000/mm3;
- Previous stroke or severe traumatic brain injury within 3 months;
- Unable to perform CT or MRI;
- History of hemorrhagic stroke or stroke of unspecified genesis;
- Multiple arterial occlusion (bilateral MCA occlusion, MCA occlusion accompanied with basilar occlusion);
- Concomitant use of indirect oral anticoagulants (warfarin) with INR > 1.7;
- Taking direct anticoagulants (heparin, heparinoids) in the previous 48 hours with an APTT value above normal;
- Taking new oral anticoagulants in the previous 48 hours with a thrombin time value above normal and the impossibility of administering the specific antagonist idarucizumab (for dabigatran) or the presence of anti-Xa activity (for rivaroxaban, apixaban and edoxaban).
- Severe liver disease, including liver failure, liver cirrhosis, portal hypertension (with esophageal varices), active hepatitis;
- Acute pancreatitis;
- Bacterial endocarditis, pericarditis;
- Arterial aneurysms, malformations of arteries and veins. Suspected dissecting aortic aneurysm;
- Cancer with an increased risk of bleeding;
- Major surgeries or severe injuries within the last 14 days, minor surgeries or invasive procedures within the last 10 days;
- Prolonged or traumatic cardiopulmonary resuscitation (more than 2 minutes);
- Hemorrhagic diathesis, including renal and hepatic failure;
- Data on bleeding or acute trauma (fracture) at the time of examination;
- Pregnant women, nursing mothers, or reluctant to use effective contraceptive measures during the period of trial.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
위약 비교기: Placebo
Placebo |
Placebo is given as a single intravenous bolus (within 5-10 seconds) immediately upon randomization |
|
실험적: Non-immunogenic staphylokinase
The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight |
The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Excellent functional outcome
기간: 90 days
|
The number of patients with excellent functional outcome defined as an mRS score 0-1 at 90 days |
90 days
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Ordinal distribution of mRS
기간: 90 days
|
Ordinal distribution of mRS at 90 days |
90 days
|
|
Functional independence outcome
기간: 90 days
|
The number of patients with functional independence defined by an mRS score 0-2 point at 90 days |
90 days
|
|
NIHSS change from baseline
기간: 7-14 days
|
NIHSS median change from baseline on discharge |
7-14 days
|
|
The rate of improvement on reperfusion
기간: 24 hours
|
The number of patients with recanalization of 2 and 3 points on the arterial occlusion scale (rAOL) 24 hours after drug administration according to CT (MRI) angiography, where 0 points - complete occlusion, 3 points - complete recanalization. |
24 hours
|
|
All-cause mortality
기간: 90 days
|
Rate of all-cause mortality within 90 days |
90 days
|
|
Poor functional outcome
기간: 90 days
|
The number of patients with poor functional outcome defined by an mRS score 5-6 point at 90 days |
90 days
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Hemorrhagic transformation
기간: 24 hours
|
Rate of hemorrhagic transformation according to The Heidelberg Bleeding Classification within 24 hours |
24 hours
|
|
Symptomatic intracranial hemorrhage
기간: 24 hours
|
Rate of symptomatic intracranial hemorrhage (sICH) (as defined by The European Cooperative Acute Stroke Study III criteria [ECASSIII] and Safe Implementation of Thrombolysis in Stroke-Monitoring Study [SITS-MOST]) within 24 hours |
24 hours
|
|
Major bleeding
기간: 90 days
|
Rate of major bleeding at 90 days (as defined by the Bleeding Academic Research Consortium (BARC) scale: type 3 and type 5) |
90 days
|
|
Serious adverse events (SAEs)
기간: 90 days
|
Rate of serious adverse events (SAEs) within 90 days |
90 days
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Nikolay A. Shamalov, MD, prof, Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency of Russia
- 연구 책임자: Sergey S. Markin, MD, prof, LLC "SuperGene"
간행물 및 유용한 링크
일반 간행물
- Gusev EI, Martynov MY, Nikonov AA, Shamalov NA, Semenov MP, Gerasimets EA, Yarovaya EB, Semenov AM, Archakov AI, Markin SS; FRIDA Study Group. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4.5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. Lancet Neurol. 2021 Sep;20(9):721-728. doi: 10.1016/S1474-4422(21)00210-6.
- Shamalov NA, Martynov MY, Yarovaya EB, Chefranova ZY, Kutsenko VA, Semenov AM, Ivanov SV, Semenov MP, Markin SS, Gusev EI; FORPI Study Group. Thrombolysis With the Non-Immunogenic Staphylokinase for Acute Ischemic Stroke in the FORPI Registry: An Observational Study. Stroke. 2026 Feb;57(2):394-403. doi: 10.1161/STROKEAHA.125.051115. Epub 2025 Nov 26.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
기타 연구 ID 번호
- FRIDA-CT
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The funder of the study is committed to the responsible sharing of data from FRIDA-CT trail. Data will be provided to any qualified investigator on reasonable request. Deidentified participant data will be available after the publication of the results of the completed study on request to the corresponding author.
IPD 공유 기간
within 90 days after request
IPD 공유 액세스 기준
Proposals will be reviewed and approved by the funder and Data and Safety Monitoring Board. Once the proposal has been approved, data can be transferred through a secure online platform after the signing of a data access agreement and a confidentiality agreement.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .